An Open-label, Rapid Initiation Study for Extended-Release Buprenorphine Subcutaneous Injection (SUBLOCADE)
Latest Information Update: 16 Apr 2021
At a glance
- Drugs Buprenorphine (Primary)
- Indications Opioid-related disorders
- Focus Adverse reactions
- Acronyms SUBLOCADE
- Sponsors Indivior
- 20 Jan 2020 Status changed from recruiting to completed.
- 05 Sep 2019 Status changed from not yet recruiting to recruiting.
- 13 Aug 2019 Planned initiation date changed from 31 Jul 2019 to 31 Aug 2019.